X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.532
+0.013 (2.45%)
Nov 4, 2024, 4:00 PM EST - Market closed
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 93 employees as of December 31, 2023. The number of employees increased by 23 or 32.86% compared to the previous year.
Employees
93
Change (1Y)
23
Growth (1Y)
32.86%
Revenue / Employee
$6,054
Profits / Employee
$189,591
Market Cap
89.59M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 93 | 23 | 32.86% |
Dec 31, 2022 | 70 | -13 | -15.66% |
Dec 31, 2021 | 83 | 11 | 15.28% |
Dec 31, 2020 | 72 | 14 | 24.14% |
Dec 31, 2019 | 58 | - | - |
Related Stocks
Company Name | Employees |
---|---|
So-Young International | 1,357 |
Agenus | 389 |
PetMed Express | 287 |
I-Mab | 220 |
WORK Medical Technology Group LTD | 216 |
HilleVax | 90 |
Chimerix | 72 |
Armata Pharmaceuticals | 66 |
XFOR News
- 3 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024 - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 3 months ago - X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 months ago - X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data - Seeking Alpha
- 4 months ago - X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial - GlobeNewsWire